Bentracimab is a monoclonal antibody commercialized by PhaseBio Pharmaceuticals, with a leading Phase III program in Bleeding And Clotting Disorders. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Bentracimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Bentracimab is expected to reach an annual total of $408 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Bentracimab Overview

Bentracimab (PB-2452 (MEDI-2452)) is under development for the treatment of major bleeding event in patients who are on ticagrelor therapy. It is a novel recombinant human monoclonal antibody antigen-binding fragment. The drug candidate is administered intravenously. The drug candidate is an antidote of ticagrelor and specifically reverses the antiplatelet effects of ticagrelor.

PhaseBio Pharmaceuticals Overview

PhaseBio Pharmaceuticals (PhaseBio) is a clinical-stage biopharmaceutical company that develops biotherapeutics for the treatment of orphan diseases and cardiopulmonary indications. The company’s pipeline products include PB2452, a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor; PB1046 is a subcutaneously-injected, sustained release analogue of the native human peptide vasoactive intestinal peptide (VIP) used for the treatment of pulmonary arterial hypertension. PhaseBio proprietary ELP Biopolymer technology platform extends the circulating half-life of proteins and peptides and also provides a sustained-release mechanism for periods of a week or longer from a single subcutaneous injection. The company develops drugs for the treatment of endocrine, metabolic and cardiovascular diseases. PhaseBio is headquartered in Malvern, Pennsylvania, the United States.

The company reported revenues of (US Dollars) US$10.8 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.3 million in FY2020. The operating loss of the company was US$107.4 million in FY2021, compared to an operating loss of US$84.9 million in FY2020. The net loss of the company was US$131.1 million in FY2021, compared to a net loss of US$98.6 million in FY2020. The company reported revenues of US$0.2 million for the second quarter ended June 2022, an increase of 77.8% over the previous quarter.

For a complete picture of Bentracimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.